Suzanne E Schindler, Douglas Galasko, Ana C Pereira, Gil D Rabinovici, Stephen Salloway, Marc Suárez-Calvet, Ara S Khachaturian, Michelle M Mielke, Chi Udeh-Momoh, Joan Weiss, Richard Batrla, Sasha Bozeat, John R Dwyer, Drew Holzapfel, Daryl Rhys Jones, James F Murray, Katherine A Partrick, Emily Scholler, George Vradenburg, Dylan Young, Alicia Algeciras-Schimnich, Jiri Aubrecht, Joel B Braunstein, James Hendrix, Yan Helen Hu, Soeren Mattke, Mark Monane, David Reilly, Elizabeth Somers, Charlotte E Teunissen, Eli Shobin, Hugo Vanderstichele, Michael W Weiner, David Wilson, Oskar Hansson
Anti-amyloid treatments for early symptomatic Alzheimer disease have recently become clinically available in some countries, which has greatly increased the need for biomarker confirmation of amyloid pathology. Blood biomarker (BBM) tests for amyloid pathology are more acceptable, accessible and scalable than amyloid PET or cerebrospinal fluid (CSF) tests, but have highly variable levels of performance. The Global CEO Initiative on Alzheimer's Disease convened a BBM Workgroup to consider the minimum acceptable performance of BBM tests for clinical use...
June 12, 2024: Nature Reviews. Neurology